Novartis announced positive results from two phase 3 clinical trials assessing Beovu (brolucizumab) 6 mg versus aflibercept 2 mg in patients with diabetic macular edema (DME). Year 2 of the pivotal KITE trial evaluated Beovu on up to 16-week dosing intervals, and the 1-year KINGFISHER study evaluated Beovu dosed every 4 weeks.1,3 Both trials demonstrated an overall well-tolerated safety profile.
Oxurion Announces Publication of Positive Phase 1 Clinical Data Evaluating THR-687 for Treatment of DME
Oxurion announced that the positive phase 1 study of THR-687, a novel, highly potent integrin agonist for the treatment of DME has just been published in Ophthalmology Science. The multicenter, dose escalation study was designed to evaluate the safety and preliminary efficacy of three dose levels of THR-687 (0.4, 1.0 or 2.5mg) in subjects with center-involved DME following a single intravitreal …
Berlin’s Dopavision raises €12M to halt myopia progression in children and adolescents; here’s how
Dopavision is a Berlin-based company developing digital therapeutics for myopia. Nearsightedness (myopia) is a vision condition in which patients can see objects near to them clearly, but objects farther away are blurry.Dopavision raises Series A roundIn a recent development, the company announced that it has raised €12M in its Series A round of funding. The round was led by Seventure …
Omni surgical system reduces IOP, medication use
The Omni surgical system reduced IOP through 3 months in patients with open-angle glaucoma, according to research presented at the American Society of Cataract and Refractive Surgery meeting. Brian Flowers, MD, presented 3-month interim data from the ORION study exploring the efficacy and safety of the Omni surgical system (Sight Sciences) in pseudophakic eyes with mild to moderate open-angle glaucoma. Patients …
Spatial technology measures association between green space exposure, myopia
Using satellite imaging techniques, researchers were able to establish an association between green space exposure at school and the change in school-specific myopia prevalence. Even a relatively small increase in green space exposure was associated with a nearly 30% lesser risk for non-myopic children to develop myopia.
Robotic scanner automates diagnostic imaging in the eye
Engineers and ophthalmologists at Duke University have developed a robotic imaging tool that can automatically detect and scan a patient’s eyes for markers of different eye diseases. The new tool, which combines an imaging scanner with a robotic arm, can automatically track and image a patient’s eyes in less than a minute, and produce images that are as clear as …
Faricimab: An Emerging Therapy for the Treatment of Neovascular Age-related Macular Degeneration
In posterior segment disorders characterized by the growth of abnormal blood vessels, the vascular endothelial growth factor (VEGF) protein is upregulated, which has led to the current standard-of-care treatments targeting this important pathway. Anti-VEGF agents have drastically improved treatment of neovascular age-related macular degeneration (nAMD) and diabetic retinopathy over the past 15 years. However, not all patients respond adequately to anti-VEGF …
Santen and Sydnexis Execute an Exclusive Licensing Agreement for SYD-101, an Investigational Treatment for Progressive Childhood Myopia
Santen and Sydnexis have signed an exclusive licensing agreement for SYD-101, Sydnexis’ investigational proprietary low-dose atropine formulation for childhood myopia, for Europe, the Middle East, and Africa (EMEA). SYD-101 is currently undergoing a large multicenter phase 3 clinical trial, the STAAR study, in Europe and the US.
Sydnexis Secures $45 Million Series B Financing
Sydnexis, Inc. today announced the completion of a $45 million Series B financing led by Visionary Ventures, Blue Stem Capital, and SC Master Fund, with participation from existing investors RA Capital Management, Longitude Capital, and Medicxi. The financing will be used to fund Sydnexis’ lead candidate, SYD-101, through completion of the fully enrolled pivotal Phase 3 STAAR study for the …
Alimera Sciences and Tanner Pharma Group Initiate Global Named Patient Program for ILUVIEN®
Alimera Sciences Europe Limited announced the initiation of a Named Patient Program for ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg globally for the treatment of diabetic macular edema (DME) and in Europe and the Middle East, for the treatment of non-infectious posterior uveitis (NIU-PS).
